Faculty Academic Productivity 2013-2014

Peer Reviewed Literature (Published) 126
Abstracts & Presentations 74
Books 2
Book Chapters 26
Journal Editorial Board Review Panels 76
Courses & Invited Lectureships 91
Extramural Grant Support (Currently Funded) 25
Industry & Clinical Trials Support 6

PEER-REVIEWED LITERATURE


124. Diaz ES, Walts AE, Karlan BY, Walsh C. Venous thromboembolism at diagnosis of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol 2013;131:541-545.


**ABSTRACTS AND PRESENTATIONS**


40. Bedroske PP, Sukov WR, Pearce KE, Hodge JC. FISH Validation for Identification of JAZF1, PHF1 and JYHWE Rearrangements in Endometrial Stromal Tumors and Discovery of an Unusual PHF1 Positive Case. Poster presented at the Association of Molecular Pathology meeting, Phoenix, AZ, November 2011.


COURSES AND INVITED LECTURES


4. **Amin MB.** Invited Lecturer. Approach to the diagnosis of adult renal tumors with clear and oxyphilic cytoplasm and those with papillary architecture. Spain Hospital Clinic in Madrid, Hospital German Trias y Pujol in Barcelona & University Hospital Virgen Macarena, Seville, Spain, August 2013.

5. **Amin MB.** Invited Lecturer. How I diagnose bladder tumors: Practical issues we all struggle with and an approach to resolve them. Spain Hospital Clinic in Madrid, Hospital German Trias y Pujol in Barcelona & University Hospital Virgen Macarena in Seville - Spain, August 2013.

6. **Amin MB.** Invited Lecturer. The Bridge from a “Population Based” to a “More Personalized” Approach. American Joint Committee on Cancer (AJCC), General Board Meeting Lecturer, AJCC Annual Meeting, Chicago, IL, September 2013.


9. **Amin MB.** Invited Lecturer. Challenging Urologic Pathology cases from which I have learned tremendously. Invited Lecturer, Genital Tract Pathology, The Royal College of Pathologists, London, UK, October 2013.


12. **Amin MB.** Invited Lecturer. The Critical Role of the Pathologist in the Multidisciplinary Team Management Approach to Prostate Cancer. Invited Lecturer, Symposium on Pathology of Prostate Cancer, Hinduja Hospital, Mumbai, India, December 2013.

13. **Amin MB.** Invited Lecturer. ISUP Vancouver Classification of Renal Neoplasia, Lecturer, Anatomic Pathology Didactics Lecture, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, January 2014.


15. **Amin MB.** Invited Lecturer. Best Practices in the Application of Immunohistochemistry to Diagnostic Urologic Pathology: Lessons from uses and abuses. 93rd Annual Meeting of the Texas Society of Pathologists, Houston, TX, January 2014.


17. **Amin MB.** Invited Lecturer. ISUP Vancouver Classification of Renal Neoplasia, Stromal Neoplasms of the Kidney, Germ Cell Tumors of the Testis and Prostate Neuroendocrine Tumors. 2nd Milan Conference on Urologic Tumors, Milan, Italy, January 2014.


20. **Amin MB.** Invited Lecturer. Epithelioid Angiomyolipoma. Faculty Lecturer, 3rd Urogenital Pathology Meeting, Mikulov, Czech Republic, June 14, 2014.


22. **Amin MB.** Invited Lecturer. Subtle patterns and common pitfalls in the diagnosis of prostate cancer; Pseudoneoplastic lesions of the urinary bladder: diagnostic criteria and implications of misdiagnosis; Challenging tumors of the urinary bladder: diagnostic, prognostic and therapeutic significance of appropriate classification; The most common clinically significant misdiagnoses in renal neoplasia and how to avoid them; and Pitfalls in the application of immunohistochemistry as a diagnostic tool in urologic pathology. Faculty Lecturer, Scientific Symposia International Surgical Pathology of Difficult to Diagnose Genitourinary, Breast, Pancreatic and Gastrointestinal Lesions Conference, Maui, HI, July 2014.

23. **Bernstein KE.** Invited Lecturer. The many roles of angiotsin converting enzyme. American Heart Association National Meeting, Dallas, TX, 2013.


26. **Bernstein KE.** Invited Lecturer. The many roles of angiotsin converting enzyme. Emory University Medical School, Atlanta, GA, 2014.

27. **Dadmanesh, F.** Invited Lecturer. HER2 testing in breast cancer: An overview. Oncology Fellowship Lecture Series, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, November 2013.

28. **Di Vizio D.** Invited Lecturer. Grand Rounds Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, August 2013

29. Di Vizio D. Invited Lecturer. Regenerative Medicine Institute Lecture Series, Cedars-Sinai Medical Center, Los Angeles, CA September 2013.
34. Di Vizio D. Invited Lecturer. ISEV workshop, Melbourne, Australia, February 2014.
37. Di Vizio D. Invited Lecturer. 10th Annual National Symposium on Prostate Cancer, Clark Atlanta University, Atlanta, GA, March 2014.
41. Di Vizio D. Invited Lecturer. Symposium session 5B - EV as cancer biomarkers, Section Chair, ISEV meeting, Rotterdam, The Netherlands, May 2014.
42. Di Vizio D. Invited Lecturer. SOCCI Lung Cancer Symposium, Los Angeles, May 2014.
43. Di Vizio D. Invited Lecturer. BATSSS Seminar Series, Cedars-Sinai Medical Center, Los Angeles, CA May 2014.
45. Korea, September 2013.
49. Di Vizio D. Invited Lecturer. Laboratory of Functional Systems Biochemistry, Kyung Hee University, Yong-in City, Republic of Korea, June 2014.
52. Huang Q. Invited Lecturer. Hematopathology case review. Ningzhou's People Hospital, April 2014.
53. Huang Q. Invited Lecturer. Hodgkin Lymphoma and Differential Diagnosis. Sir Run Run Shaw Hospital, Zhejiang University, April 2014.
56. Klapper E. Invited Lecturer. Red Blood Cell Genotyping; One Hospital's Experience; Presented at the Blood Products. Advisory Committee Meeting of the Food and Drug Administration, Silver Spring, MD, March 2014.
59. Luthringer D. Invited Lecturer. Surgical Pathology Slide Seminar II. Asia Pacific Division of the International Academy of Pathology (IAP). Busan, Korea, September 2013.
63. Marchevsky A. Invited Lecturer. Unusual lung cases. AMR Slide Seminars, Tel Aviv, Israel, July 2013.
64. Marchevsky A. Invited Lecturer. Introduction to Evidence Based Pathology and Systematic Reviews. IARC/WHO working group, Sloan Kettering Cancer Center, New York, December 2013.
66. Marchevsky A. Invited Lecturer. Evidence Based Pathology. Ichilov Medical Center/Tel Aviv University Medical School. Tel Aviv, Israel, February 2014.
67. Marchevsky A. Invited Lecturer. Evidence-Based Pulmonary Pathology, University of Pittsburgh, May 2014.
80. Morgan M. Invited Lecturer. MALDI-TOF and Other Advances in Microbiology. CLMA Annual Spring Meeting, Duarte, CA, March 2014.
85. Rutgers J. Invited Lecturer. Synoptic reporting of colorectal carcinoma, Cedars-Sinai Medical Center, Los Angeles, CA, July 2013.
86. Schreck R. Invited Lecturer. Organization of the Human Genome. UCLA Inter campus Medical Genetics course, University of California, Los Angeles, CA, 2014.
87. Schreck R. Section Director for lecture series for Genetics Core, Graduate Program in Biomedical Science and Translational Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 2013-2014.
88. Sobhani K. Invited Lecturer. Immunoassays: Detection Schemes and How They Work. In-service Course, Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine, Los Angeles, CA, March, 2014.
89. Sobhani K. Invited Lecturer. Thyroid Disorders and the Clinical Laboratory In-service Course, Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine, Los Angeles, CA, May, 2014.

**EXTRAMURAL GRANT SUPPORT (FUNDED)**

### Amin MB

<table>
<thead>
<tr>
<th>NIH R21</th>
<th>P. Santangelo (PI); M. Amin (Co-PI)</th>
<th>2011-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Characterizing gene regulation with single molecule sensitive probes (Total: $500,000).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To quantify mRNA number and mRNA-protein interactions in prostate cancer cellular models and tissue tumor samples using single molecule sensitive probes, a modified proximity ligation assay and rolling circle amplification.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIH IG20RR030860</th>
<th>S. Melmed (PI); M. Amin (Faculty)</th>
<th>2010-2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Cedars-Sinai Biobank and Translational Research Core Facility (Total: $9,552,872).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To build a centralized human Tissue Repository research core facility at Cedars-Sinai Medical Center.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCI/RTOG</th>
<th>M. Amin (PI)</th>
<th>2006-2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Radiation Therapy Oncology Group. National Institutes for Health (NIH) 2U10 CA 02 21661-29 (Curran). Pathology Committee (Total: $13,798,229 - 01/01/08-12/31/13) Pathology Chair for protocols RTOG 9408, 9910, 415, 232, 521, 526, 534, 126, 612.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: Fee for service retrospective and prospective review of prostate cancer cases.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prostate Cancer Foundation</th>
<th>M. Amin (PI)</th>
<th>2010-2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Active surveillance for Prostate Cancer (Total: $5,000,000).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: A biorepository of patients on active surveillance (biopsies, blood samples and clinical information) is enabled to develop a resource that will allow investigation of new biomarkers for the prediction of patients at risk for progression.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIH/1 P01 CA98912</th>
<th>L. Chung (PI); M. Amin (Co-PI)</th>
<th>2009-2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Prostate Cancer Bone Metastasis: Biology and Targeting ($1,298,070).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To elucidate the biology and molecular pathways involved in the interaction between stromal cells of the bone or the prostate and malignant prostate cancer cells.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bernstein, KE**

### ACTIVE

<table>
<thead>
<tr>
<th>NHLBI 9R01HL110353-28</th>
<th>K. Bernstein (PI)</th>
<th>1988-2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: RAS and Injury ($250,000 Direct per year).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goals: To 1) investigate the hypertensive and inflammatory response of mouse models having high or low levels of AcSDKP; 2) investigate the precise pathophysiologic consequences of this peptide; 3) investigate which inflammatory cells mediate the increased inflammatory response in mouse models having high levels of AcSDKP; and 4) investigate the biochemical basis for the enhanced inflammatory response present in N-KO mice.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIDDK IR01DK098382-01A1</th>
<th>S. Gurley (PI); K. Bernstein (Subcontract)</th>
<th>2014-2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Actions of Angiotensin II Along the Nephron to Regulate Blood Pressure ($34,800 Direct per year subcontract).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Aims of this grant are 1) To determine how AT1 receptors in the proximal tubule directly regulate proximal tubule function, add 2) To define mechanisms for paracrine control of distal nephron function by AT1 receptors in proximal tubule. My subcontract is to assist in the analysis of mice that lack renal ACE.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIDDK IR03DK101592-01</th>
<th>R. Gonzalez (PI); K. Bernstein (Co-PI)</th>
<th>2014-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Renal ACE, Salt sensitivity and Blood Pressure Control ($125,000 Direct per year).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To study the role of the intrarenal renin-angiotensin system.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PENDING

<table>
<thead>
<tr>
<th>NHLBI 2P01HL058000-17A1</th>
<th>D. Harrison (PI); K. Bernstein (Leader, Project 3)</th>
<th>2014-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Inflammation, immunity and cardiovascular disease ($215,000 - Project 3).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To study the role of inflammation in hypertension and atherosclerosis. These goals are to study the role of ACE in the innate, adaptive and terminal immune response accompanying hypertension.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NHLBI 1R01HL233430-01A1</th>
<th>K. Bernstein (PI)</th>
<th>2015-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title: Role of ACE in inflammation and hypertension (Total $250,000).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goal: To study the role of ACE in the adaptive and terminal immune response accompanying hypertension. This grant has some additional experiments not in the Harrison grant listed above.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Title: Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer (Total $493,699)
NIH/NCI 1R01CA182438-01A1   H. Kim, B. Knudsen (PIs)   2014-2019
Goals: To validate an RNA biomarker panel for the prediction of upgrading and upstaging from the prostate needle biopsy to the radical prostatectomy. Of African-American ethnicity on the biomarker signatures.

Goal: To 1) qualify biomarkers in prostate needle biopsies for predicting adverse pathology in men considering active surveillance, and 2) to test the effects of African-American ethnicity on the biomarker signatures.

Di Vizio D
NCI/NIH R00CA131472-01A1 D. Di Vizio (PI) 2008-2013
Title: Fatty Acid Synthase, Caveolin-1 and Membrane Microdomains in Prostate Cancer (Total $715,294).
Goal: To determine the contribution of Fatty Acid Synthase and Caveolin-1 to altered membrane dynamics in aggressive prostate cancer.

Avon Foundation for Women D. Di Vizio (PI) 2013-2015
Title: Avon Foundation for Women (Total $300,000).
Goal: To investigate miRNA biomarkers in circulating large extracellular vesicles that may identify patients with aggressive breast cancer.

Martz Fund Translational Breast Cancer Award M. Freeman (PI); D. Di Vizio (Co-PI) 2011-2014
Title: DIAPH3 and the Amoeboid Transition in Breast Cancer (Total $220,000)
Goal: The goals of this project will be 1) to evaluate the significance of DRF3 in regulating the amoeboid phenotype in mammary epithelial and breast cancer cells, and 2) to develop the means to identify the amoeboid molecular signature in human breast tumors.

NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: Biomarkers of Response to Treatment with XL184 in the Bone (Total $150,000).
Goal: The novel concept that XL184 through inhibition of c-MET inhibits cellular metabolism will be examined with two major goals in mind. (A) First, we will determine the direct cytotoxic effects of XL184 in patient biopsies and evaluate whether inhibition of fatty acid metabolism and c-MYC expression correlate with the response of the cancer cells to the treatment. (B) Second, we will determine c-MET’s role in the treatment response to XL184.

NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: In vivo effects of Sulforaphane supplementation on normal human prostate (Total $18,731).
Goal: This dual PI project will identify intermediate biomarkers of prostate cancer prevention by sulforaphane supplementation prior to radical prostatectomy. The biomarkers are based on novel molecular hypotheses and measured in human tissues that are obtained in a double blinded randomized nutritional intervention trial.

NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: Prostate Cancer Bone Metastasis: Biology and Targeting ($1,298,070).
Goal: To elucidate the biology and molecular pathways involved in the interaction between stromal cells of the bone or the prostate and malignant prostate cancer cells.

NIH/NCI 2R01CA108646-07A1 B. Knudsen (PI) 2012-2017
Title: TGF Beta Signals in Prostate Stromal-Epithelial Interactions (Total $292,148).
Goal: To study the mechanism of the epigenetic changes in the tumor microenvironment and its role in prostate cancer progression and understand the role of stromal epigenetic signaling.

ACTIVE
Prostate Cancer Foundation B. Knudsen (PI) 2011-2015
Title: Biomarkers of Response to Treatment with XL184 in the Bone (Total $150,000).
Goal: The novel concept that XL184 through inhibition of c-MET inhibits cellular metabolism will be examined with two major goals in mind. (A) First, we will determine the direct cytotoxic effects of XL184 in patient biopsies and evaluate whether inhibition of fatty acid metabolism and c-MYC expression correlate with the response of the cancer cells to the treatment. (B) Second, we will determine c-MET’s role in the treatment response to XL184.

NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: In vivo effects of Sulforaphane supplementation on normal human prostate (Total $18,731).
Goal: This dual PI project will identify intermediate biomarkers of prostate cancer prevention by sulforaphane supplementation prior to radical prostatectomy. The biomarkers are based on novel molecular hypotheses and measured in human tissues that are obtained in a double blinded randomized nutritional intervention trial.

NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: Prostate Cancer Bone Metastasis: Biology and Targeting ($1,298,070).
Goal: To elucidate the biology and molecular pathways involved in the interaction between stromal cells of the bone or the prostate and malignant prostate cancer cells.

INDEP
NIH/NCI 1R01CA131255-01A1 B. Knudsen (PI) 2009-2015
Title: TGF Beta Signals in Prostate Stromal-Epithelial Interactions (Total $292,148).
Goal: To study the mechanism of the epigenetic changes in the tumor microenvironment and its role in prostate cancer progression and understand the role of stromal epigenetic signaling.

PENDING
DOD PCRP PC1304848 B. Knudsen, Garraway, Stern (PIs) 2014-2017
Title: Genomic Biomarkers To Identify Indolent Prostate Cancer and Safely Defer Treatment (Total $493,699)
Goals: To validate an RNA biomarker panel for the prediction of upgrading and upstaging from the prostate needle biopsy to the radical prostatectomy.

NIH/NCI 1R01CA182438-01A1 H. Kim, B. Knudsen (PIs) 2014-2019
Title: Genomic Biomarkers To Identify Indolent Prostate Cancer and Safely Defer Treatment (Total $493,699)
Goals: To validate an RNA biomarker panel for the prediction of upgrading and upstaging from the prostate needle biopsy to the radical prostatectomy.
Nast CC
NIH/ORD
M. Kretzler (PI); C. Nast (Consultant) 2009-2014
Title: Nephrotic Syndrome Rare Disease Clinical Research Network (Total $10,250,000).
Goal: Describe and correlate clinical, morphological, proteomic and molecular data from patients and their biological samples to understand the pathogenesis and treatment targets of nephrotic glomerulopathies.

NIH/ORD/Neptune Pilot Grant
J. Hodgin (PI); C. Nast (Co-PI) 2013-2014
Title: Significance of focal sclerosis in immune complex glomerulonephritis (Total $50,000).
Goal: Determine the pathogenesis and significance of segmental glomerulosclerosis in patients with IgA and membranous nephropathies.

Pillai R
UCLA CTSI Voucher Award
R. Pillai (PI) 2014-2015
Title: UCLA Genotyping and Sequencing Core (GENoSeq) (Total $10,000).
Goal: Use of core resources in genomic analysis of plasmablastic lymphomas.

Shen X (Gregory)
ACTIVE
American Heart Association 13BGIA14680069
X. Shen (PI) 2013-2014
Title: The impact of angiotensin converting enzyme (ACE) on MHC class I ($63,636 Direct per year).
Goal: To study the role of ACE on MHC class I peptide maturation and the precise shaping of the MHC class I repertoire in response to virus and other stimuli. No overlap.

NHLBI 9R01HL110353-27
K. Bernstein (PI); X. Shen (Co-PI) 1988-2016
Title: RAS and Injury ($250,000 Direct).
Goals: To 1) investigate the hypertensive and inflammatory response of mouse models having high or low levels of AcSDKP; 2) investigate the precise pathophysiologic consequences of this peptide; 3) investigate which inflammatory cells mediate the increased inflammatory response in mouse models having high levels of AcSDKP; and 4) investigate the biochemical basis for the enhanced inflammatory response present in N-KO mice No overlap.

PENDING
NHLBI 2P01HL058000-17A1
D. Harrison (PI); X. Shen (Co-PI) 2014-2019
Title: Inflammation, immunity and cardiovascular disease ($215,000 - Project 3).
Goals: To study 1) the role of inflammation in hypertension and atherosclerosis; and 2) the role of ACE in the innate, adaptive and terminal immune response accompanying hypertension.

NHLBI 1R01HL123430-01A1
K. Bernstein (PI); X. Shen (Co-PI) 2015-2019
Title: Role of ACE in inflammation and hypertension (Total $250,000).
This grant is similar to the PPG submission. The goals are to study the role of ACE in the adaptive and terminal immune response accompanying hypertension.

NIAID, NIH 1R21AI114965-01
X. Shen (PI) 2014-2016
Title: Carboxypeptidase ACE and MHC class I presentation (Total $125,000).
Goal: To study the role of ACE on MHC class I peptide maturation and shaping of the MHC class I repertoire.

AHA Grant in Aid 15GRNT23020019
X. Shen (PI) 2015-2016
Title: ACE, inflammation and hypertension (Total $63,636).
Goal: To study ACE and the formation and display of hypertensive epitopes. It is also to study MDSC and hypertension.

Walts AE
ACTIVE
DoD W81XWH-13-OCR-P-TLA
S. Orsulic (PI); A. Walts (Consultant) 2014-2016
Ovarian Cancer Clinical Translation Leverage Award
Title: Tumor Microenvironment Gene Signature as a Prognostic Classifier and Therapeutic Target (Total $247,190).
Goal: To develop a clinically applicable discriminatory transcriptome signature assay for predicting poor outcome in ovarian cancer.

Alex’s Lemonade Stand Foundation
S. Orsulic (PI); A. Walts (Consultant) 2013-2015
Title: An Intersection of Cell Metabolism and Differentiation in Childhood Sarcomas (Total $250,000).
Goal: To identify and test new therapeutic targets for rhabdoid tumors.

PENDING
NIH-NCI R21CA194626
S. Orsulic (PI); A. Walts (Consultant) 2015-2017
Title: Why is Ovarian Cancer Primarily a Disease of Postmenopausal Women? (Total $250,000).
Goal: The goal of this project is to determine which molecular and biological factors influence susceptibility to cancer risk in postmenopausal women.

DOD OC140415
S. Orsulic (PI); A. Walts (Consultant) 2015-2018
Title: Why is the ovary fertile soil for cancer seeding? (Total $300,000).
Goal: To understand which aspects of the ovarian microenvironment are conducive to implantation of tubal cancer cells.

INDUSTRY & CLINICAL TRIALS SUPPORT
Amin MB
RTOG Protocol 0526
M. Amin (Pathology Chairman) 2007-2013
Title: A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy.
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Support) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy

Klapper E
CD-133 DC Vaccine, IRB 30646 J. Rudnick (PI) 2014-2015
Immunological targeting of CD133 in recurrent glioblastoma: A translational and clinical study of an autologous CD-133 DC vaccine. Investigate the effect of tumor vaccine in the treatment of recurrent glioblastoma

CSMC-IIT-Hu-Neurosphere, IRB 33203 J. Hu (PI) 2013-2014
A phase 1 trial of vaccination with autologous dendritic cells pulsed with lysate from an allogeneic glioblastoma stem-like cell line for patients with newly diagnosed or recurrent glioblastoma. Investigate the effect of tumor vaccine in the treatment of newly diagnosed or recurrent glioblastoma

AGS-003-007 (ADAPT), IRB 29298 R. Figlin (PI) 2013-2014
An international phase 3 randomized trial of autologous dendritic cell immunotherapy (AGS 003) plus standard treatment of advanced renal cell carcinoma (Argos therapeutics sponsored).

Adipose-derived regenerative cells in the treatment of patients with chronic ischemic Heart disease not amenable to surgical or interventional revascularization II.